St. Jude Beats Estimates, With 'Small Impact' From Boston Sci Absence
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical's better-than-expected first quarter benefited from Boston Scientific's month-long hiatus from the U.S. implantable defibrillator market, but that was not the pivotal factor, according to the company
You may also be interested in...
Boston Scientific Tries To Climb Back Up From ICD Market Share Spill
Boston Scientific is banking on intense communication with physicians and new product launches to eventually pull its ICD business back to its pre-sales-suspension standing, but the firm acknowledges that it will be playing catch-up for the foreseeable future
Boston Scientific Tries To Climb Back Up From ICD Market Share Spill
Boston Scientific is banking on intense communication with physicians and new product launches to eventually pull its ICD business back to its pre-sales-suspension standing, but the firm acknowledges that it will be playing catch-up for the foreseeable future
Boston Scientific Resumes Most, Not All, Implantable Defibrillator Shipments
Boston Scientific resumed shipments of virtually all of its implantable defibrillators April 15 following retrospective clearance by FDA of two manufacturing changes